Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + Dabrafenib + Trametinib in BRAF-Mutant Anaplastic Thyroid Cancer
NCT04238624Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2020
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in anaplastic thyroid cancer (ATC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2020; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT04238624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238624.